Mediator-neutralizing antibody
Antibody mediator neutralization
- Catches a soluble mediator before it reaches its receptor — the largest antibody family
- Cytokines: TNF-α, IL-5, IL-6, IL-13, IL-17, IL-23, TSLP, BLyS, IgE
- Ustekinumab binds the shared p40 subunit (IL-12 AND IL-23); guselkumab, risankizumab and mirikizumab bind p19 only
- Bimekizumab recognizes IL-17A and IL-17F with two identical arms — not a bispecific
- Catches a soluble mediator before it reaches its receptor — the largest antibody family
- Cytokines: TNF-α, IL-5, IL-6, IL-13, IL-17, IL-23, TSLP, BLyS, IgE
- Ustekinumab binds the shared p40 subunit (IL-12 AND IL-23); guselkumab, risankizumab and mirikizumab bind p19 only
- Bimekizumab recognizes IL-17A and IL-17F with two identical arms — not a bispecific
Drugs with this mechanism (18)
- Adalimumab — Subcutaneous TNF antibody for arthritis, psoriasis, IBD, and uveitis.
- Belimumab — BAFF antibody for systemic lupus and lupus nephritis; lowers flares without depleting B cells.
- Bimekizumab — The only antibody blocking BOTH IL-17A and IL-17F; candidiasis risk rises with the dual block.
- Fremanezumab — CGRP ligand antibody dosed monthly or quarterly for migraine.
- Galcanezumab — CGRP ligand antibody for migraine and cluster headache.
- Guselkumab — IL-23 p19 antibody for psoriasis, psoriatic arthritis and inflammatory bowel disease.
- Infliximab — Chimeric TNF antibody given IV; the oldest of the anti-TNF agents.
- Ixekizumab — IL-17A antibody for plaque psoriasis, psoriatic arthritis and axial spondyloarthritis.
- Lebrikizumab — IL-13 antibody for moderate-to-severe atopic dermatitis.
- Mepolizumab — IL-5 antibody for eosinophilic asthma and eosinophilic systemic disease.
- Mirikizumab — IL-23 p19 antibody for ulcerative colitis and Crohn disease.
- Omalizumab — Anti-IgE antibody for allergic asthma, chronic urticaria and food allergy; anaphylaxis boxed warning.
- Risankizumab — IL-23 p19 antibody spanning plaque psoriasis, psoriatic arthritis and inflammatory bowel disease.
- Secukinumab — IL-17A antibody for psoriasis, psoriatic arthritis, axial disease and hidradenitis suppurativa.
- Siltuximab — IL-6 antibody for Castleman disease.
- Tezepelumab — Upstream TSLP antibody for severe asthma; no eosinophil or allergic phenotype is required.
- Tralokinumab — IL-13 antibody for moderate-to-severe atopic dermatitis.
- Ustekinumab — IL-12/23 p40 antibody for psoriasis, psoriatic arthritis, and inflammatory bowel disease.
All mechanisms · Open Antibody mediator neutralization in the interactive console ↗